Effect of LY3314814 on the Pharmacokinetics of Rosuvastatin in Caucasian Healthy Subjects
Latest Information Update: 06 Nov 2019
At a glance
- Drugs Lanabecestat (Primary) ; Rosuvastatin
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 05 Aug 2019 Results assessing BCRP inhibition potential of lanabecestat on the pharmacokinetics of rosuvastatin, a probe for BCRP activity published in the Journal of Clinical Pharmacology
- 19 Jun 2017 Status changed from active, no longer recruiting to completed.
- 03 May 2017 Status changed from recruiting to active, no longer recruiting.